Regeneron Pharmaceuticals Inc. Reports Robust Second‑Quarter Performance
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) released its second‑quarter 2026 financial and operating results on July 30, 2026. The company reported revenues of $4.3 billion, an increase of 17 % compared with the same period in 2025. Net sales for the key product Dupixent grew 38 % to an all‑time high of $6.0 billion worldwide, while EYLEA HD U.S. net sales rose 52 % to $596 million. Global sales for Libtayo increased 30 % to a new all‑time high.
Earnings. Regeneron recorded earnings of $1.296 billion ($12.23 per share), down from $1.391 billion ($12.81 per share) in the same quarter last year. After adjusting for non‑recurring items, adjusted earnings were $1.543 billion ($14.58 per share), exceeding analyst expectations.
Dividend. In a separate announcement, Regeneron declared a quarterly dividend of $0.94 per share, to be paid on a date to be determined by the board.
Market reaction. Shares of Regeneron rose following the earnings report. The price closed at $695.42 on July 28, 2026, after a high of $821.11 in January and a low of $541 in October. The company’s market capitalization stood at $67.88 billion, with a price‑earnings ratio of 16.37.
Outlook. Regeneron’s management updated its full‑year 2026 guidance, maintaining strong expectations for Dupixent and EYLEA HD. The company highlighted continued growth in its portfolio and noted the positive impact of high‑dose EYLEA on its quarterly results.
The company’s performance underscores its position as a leading biopharmaceutical player in the United States, specializing in the discovery, development, and commercialization of products for serious medical conditions. Regeneron’s stock remains listed on the Nasdaq exchange, with its official website at www.regeneron.com .
